Nevertheless, the above common features of coronary blood flow impairment in all forms of heart failure render them a valid target also for all established treatment strategies (statins, ACE inhibitors, AT1 blockers), but also a potential caveat (beta blockers: increased diastolic duration vs. increased vasoconstriction [86, 95]) and a worthwhile target in the study of novel treatment options, e.g., neprilysin or sodium glucose transporter 2 (SGLT2) inhibition. This evidence concerns the gene ACE and heart failure.